Steroid-free regimen with daclizumab, mycophenolate mofetil, and tacrolimus in liver transplant recipients

By Figueras J.   Bernardos A.   Prieto M.   Gomez M.   Rimola A.   Ortiz de Urbina J.   Cuervas-Mons V.   de la Mata M.   Dominguez-Granados R.  

Transplantation Proceedings, Vol. 34, Iss. 5, 2002-08 ,pp. : 1511-1513

Elsevier

Access to resources Recommend Favorite

Induction immunosuppression with interleukin-2 receptor antibodies (basiliximab and daclizumab) in renal transplant recipients

By Nair M.P.   Nampoory M.R.N.   Johny K.V.   Costandi J.N.   Abdulhalim M.   El-Reshaid W.   Al-Muzairai I.   Ninan V.T.   Samhan M.   Al-Mousawi M.  

Transplantation Proceedings, Vol. 33, Iss. 5, 2001-08 ,pp. : 2767-2769

Elsevier

Access to resources Recommend Favorite

Efficacy and safety of daclizumab induction for primary kidney transplant recipients in combination with tacrolimus, mycophenolate mofetil, and steroids as maintenance immunosuppression

By Ciancio G.   Burke G.W.   Suzart K.   Vaidya A.   Roth D.   Kupin W.   Mattiazzi A.   Rosen A.   Esquenazi V.   Miller J.  

Transplantation Proceedings, Vol. 35, Iss. 2, 2003-03 ,pp. : 873-874

Elsevier

Access to resources Recommend Favorite

Daclizumab induction as an immunosuppressive regimen for renal transplant recipients from non-heart-beating donors

By Sanchez-Fructuoso A.I.   Prats D.   Marques M.   Ridao N.   Conesa J.   Garcia Mena M.   Torrente J.   Barrientos A.  

Transplantation Proceedings, Vol. 35, Iss. 5, 2003-08 ,pp. : 1689-1690

Elsevier

Access to resources Recommend Favorite

Daclizumab versus anti-thymocyte globulin-fresenius as induction therapy for low-risk kidney transplant recipients

By Abou-Jaoude M.M.   Ghantous I.   Najm R.   Afif C.   Almawi W.Y.  

Transplantation Proceedings, Vol. 35, Iss. 7, 2003-11 ,pp. : 2731-2732

Elsevier

Access to resources Recommend Favorite